DanielChangChoMD

PubMed

• 17 citations
  First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.
  Elizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, Daniel C Cho, Sarah P Blagden, Dominik Berthold, Dana B Cardin, Maria Vieito, Rowan E Miller, Prashanth Har...> ;Journal for Immunotherapy of Cancer. 2022 Oct 1
• 20 citations
  Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
  Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Osama Rahma, Daniel C Cho, Naiyer A Rizvi, Mario Sznol, Jose Lutzky, Julie E B...> ;Journal for Immunotherapy of Cancer. 2022 Aug 1
• 9 citations
  Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
  Nizar M Tannir, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Arjun V Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal Choudhur...> ;Journal for Immunotherapy of Cancer. 2022 Apr 1
• 125 citations
  Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
  Patrick Y. Wen, Alexander Stein, Martin J. van den Bent, Jacques De Greve, Antje Wick, Filip de Vos, Nikolas von Bubnoff, Myra E. van Linde, Albert Lai, Gerald W. Prag...> ;The Lancet. Oncology. 2021 Nov 24
• 58 citations
  Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.
  David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, James M G Larkin, Rustem A Gafanov, Mark D Kochenderfer, Niels Viggo Jensen, Frede Donskov, Jahangeer Malik, Alexan...> ;Journal of Clinical Oncology. 2021 Mar 20
• 6 citations
  Emerging Therapies for Advanced Clear Cell Renal Cell Carcinoma.
  Alexander T Toth, Daniel C Cho> ;Journal of Kidney Cancer and VHL. 2020 Dec 14
• 46 citations
  PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
  Danny Rischin, Marta Gil-Martin, Antonio González-Martín, Irene Brana, June Y. Hou, Daniel Cho, Gerald Steven Falchook, Silvia C. Formenti, Salma K. Jabbour, Kathleen ...> ;Gynecologic Oncology. 2020 Nov 1
• 8 citations
  Novel Therapeutics Affecting Metabolic Pathways.
  Salman Punekar, Daniel C Cho> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2019 May 17
• 184 citations
  Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose...
  Toni K. Choueiri, James Larkin, Mototsugu Oya, Fiona C Thistlethwaite, Marcella Martignoni, Paul Nathan, Thomas Powles, David F. McDermott, Paul B. Robbins, David D. C...> ;The Lancet. Oncology. 2018 Apr 1
• 14 citations
  Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook
  Daniel C. Cho> ;Biodrugs. 2014 Feb 25
• Two Phase 2 Trials of the Novel Akt Inhibitor Perifosine in Patients with Advanced Renal Cell Carcinoma After Progression on Vascular Endothelial Growth Factor-Targete...
  Daniel Cho, MD> ;Wiley.
• 5 citations
  Therapeutic challenges in advanced renal cell carcinoma
  Daniel C Cho> ;Clinical Practice. 2013 Jan 1
• Join now to see all